McKesson Corp. has priced a $2.25 billion leveraged loan for its medical‑surgical unit, setting the stage for a forthcoming initial public offering. The deal signals the company’s intent to raise capital ahead of a market debut, a move that could reshape its capital structure and provide fresh funds for expansion to fuel future acquisitions and service growth.

Leveraged loans are a common funding tool for firms preparing to go public, allowing issuers to lock in rates before market conditions shift. By pricing the borrowing now, McKesson can secure favorable terms and demonstrate financial discipline to potential investors, a factor that often influences early trading performance in the months following the IPO launch.

The loan’s size positions McKesson among the larger medical‑surgical lenders, underscoring the unit’s robust revenue base and growth prospects. Investors will watch how the proceeds are allocated—whether for debt reduction, capital expenditures, or strategic acquisitions—since those choices can alter the unit’s risk profile and valuation multiples which could push the stock above its current valuation.

Market participants will gauge the IPO’s timing against broader healthcare funding trends, noting that a well‑priced leveraged loan can signal managerial confidence. The transaction also provides a benchmark for other specialty units considering public markets, potentially spurring a wave of similar offerings and could influence the pricing strategies of other mid‑cap healthcare firms.